Hee-jun Gregory Kim, MD | |
706 W Barnard St, Glennville, GA 30427 | |
(912) 654-2460 | |
(912) 654-1457 |
Full Name | Hee-jun Gregory Kim |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 706 W Barnard St, Glennville, Georgia |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1275540932 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 26317 (Georgia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Hee-jun Gregory Kim, MD 706 W Barnard St, Glennville, GA 30427-9677 Ph: (912) 654-2460 | Hee-jun Gregory Kim, MD 706 W Barnard St, Glennville, GA 30427 Ph: (912) 654-2460 |
News Archive
European healthcare is steadily improving, in spite of alarm bells about financial crisis austerity measures, aging population and migration turmoil.
The George W. Bush Institute is forming a public-private partnership to use PEPFAR's existing infrastructure of doctors, nurses and clinics to expand screening and treatment of women for cervical cancer and perform breast cancer education in the developing world, the Wall Street Journal reports.
"Leading makers of antiwrinkle drugs, breast implants and other appearance-related products are trying to derail a proposed tax on elective cosmetic surgery in the Senate's health-overhaul bill," The Wall Street Journal reports. "The proposed 5% levy - dubbed the 'Botax' after the antiwrinkle treatment product Botox - would raise an estimated $5.8 billion over 10 years."
Scientists at Virginia Commonwealth University Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The study's findings, published in today's edition of the journal "Blood," are the first to demonstrate the synergistic, anti-myeloma effects of this combination regimen both in vitro and in vivo.
Roche announced today that the U.S. Food and Drug Administration approved the cobas HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical cancer in women 25 and older. The approval follows the March 12 unanimous recommendation from the Microbiology Devices Panel of the FDA's Medical Devices Advisory Committee, making the cobas HPV Test the first and only HPV test in the United States approved for first-line primary screening.
› Verified 2 days ago